Pharmanext

Pharmanext is a South Korean biotechnology company specializing in the development of next-generation protein degraders using its proprietary Proteolysis-targeting chimera (PROTAC) platform. The company focuses on addressing "undruggable" targets in oncology, with a primary emphasis on hormone-driven cancers such as prostate and breast cancer. By leveraging the body's natural ubiquitin-proteasome system, Pharmanext aims to selectively degrade disease-causing proteins rather than simply inhibiting them. The company's pipeline includes several pre-clinical candidates targeting the androgen and estrogen receptors. Pharmanext is positioned as a key player in the emerging targeted protein degradation (TPD) space within the Asian biotech ecosystem.